logo.jpg
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
October 12, 2021 08:35 ET | Vallon Pharmaceuticals Inc.
- Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR ...
logo.jpg
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update
September 16, 2021 11:05 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
logo.jpg
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 09:15 ET | Vallon Pharmaceuticals Inc.
- Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple...
logo.jpg
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
April 13, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...
logo.png
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
November 03, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Company to host conference call and webcast on Tuesday, November 10 at 8:30 a.m. ET Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
logo.png
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
October 21, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Preliminary baseline subject demographics and disease characteristics in a Phase 3 clinical trial of the safety and efficacy of lenabasum in dermatomyositis (DETERMINE)Cannabinoid receptor type 2...
Logo.jpg
Endonovo Therapeutics Announces Reverse Stock Split
October 31, 2019 12:43 ET | Endonovo Therapeutics, Inc.
 Los Angeles, CA, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced that it had filed a preliminary information statement...
Logo.jpg
Endonovo Therapeutics Appoints Dr. William Li as Strategic Advisor to the CEO
September 30, 2019 09:00 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announces it has appointed Dr. William Li as Strategic Advisor to...
provectus_logo.jpg
PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA
February 12, 2019 07:30 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to small...
Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®
October 20, 2017 07:30 ET | Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that clinical study findings of OCR-002 (ornithine...